Suppr超能文献

神经纤维瘤病的新进展?2009 年 NF 会议记录:新前沿。

What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.

机构信息

The Wistar Institute, Philadelphia, Pennsylvania, USA.

出版信息

Am J Med Genet A. 2010 Feb;152A(2):269-83. doi: 10.1002/ajmg.a.33189.

Abstract

The NF Conference is the largest annual gathering of researchers and clinicians focused on neurofibromatosis and has been convened by the Children's Tumor Foundation for over 20 years. The 2009 NF Conference was held in Portland, Oregon from June 13 to June 16, 2009 and co-chaired by Kathryn North from the University of Sydney and The Children's Hospital at Westmead, Sydney, Australia; and Joseph Kissil from the Wistar Institute, Philadelphia. The Conference included 80 platform presentations in 9 sessions over 4 days; over 100 abstracts presented as posters; and three Keynote presentations. To date, there have been tremendous advances in basic research in the pathogenesis of neurofibromatosis, and more recently in progress toward identifying effective drug therapies and the commencement of neurofibromatosis clinical trials. The NF Conference attendees have significantly increased (doubling from 140 in 2005 to 280 attending in 2009) with a significant increase in attendance of physicians and clinical researchers. Correspondingly the NF Conference scope has expanded to include translational research, clinical trials and clinical management issues while retaining a core of basic research. These themes are reflected in the highlights from the 2009 NF Conference presented here.

摘要

NF 大会是专注于神经纤维瘤病的研究人员和临床医生最大的年度聚会,由儿童肿瘤基金会组织,已经举办了 20 多年。2009 年 NF 大会于 2009 年 6 月 13 日至 6 月 16 日在俄勒冈州波特兰举行,由澳大利亚悉尼大学和西悉尼儿童医院的 Kathryn North 与费城威斯达研究所的 Joseph Kissil 共同担任大会主席。大会包括 4 天 9 个分会场的 80 个专题演讲;100 多个海报摘要;以及 3 个主题演讲。迄今为止,神经纤维瘤病发病机制的基础研究取得了巨大进展,最近在确定有效药物治疗方法和开始神经纤维瘤病临床试验方面也取得了进展。NF 大会的参会人数显著增加(从 2005 年的 140 人增加到 2009 年的 280 人),医生和临床研究人员的参会人数显著增加。相应地,NF 大会的范围扩大到包括转化研究、临床试验和临床管理问题,同时保留了核心的基础研究。这些主题反映在 2009 年 NF 大会的亮点中。

相似文献

1
What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.
Am J Med Genet A. 2010 Feb;152A(2):269-83. doi: 10.1002/ajmg.a.33189.
3
From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Am J Med Genet A. 2019 Jun;179(6):1098-1106. doi: 10.1002/ajmg.a.61112. Epub 2019 Mar 25.
5
The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
Am J Med Genet A. 2017 Jun;173(6):1714-1721. doi: 10.1002/ajmg.a.38239. Epub 2017 Apr 24.
6
Neurofibromatosis.
Eur J Med Res. 2009 Mar 17;14(3):102-5. doi: 10.1186/2047-783x-14-3-102.
7
Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.
Acta Neuropathol. 2012 Mar;123(3):369-80. doi: 10.1007/s00401-011-0905-0. Epub 2011 Nov 16.
9
Neurofibromatosis. A review of the clinical problem.
Ann N Y Acad Sci. 1986;486:1-13. doi: 10.1111/j.1749-6632.1986.tb48057.x.

引用本文的文献

4
Advances in the treatment of neurofibromatosis-associated tumours.
Nat Rev Clin Oncol. 2013 Nov;10(11):616-24. doi: 10.1038/nrclinonc.2013.144. Epub 2013 Aug 13.
5
The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2.
J Neurol Surg B Skull Base. 2012 Apr;73(2):104-11. doi: 10.1055/s-0032-1301396.
6
Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.
Oncogene. 2013 Jul 25;32(30):3491-9. doi: 10.1038/onc.2012.374. Epub 2012 Oct 8.
7
Secretome survey of human plexiform neurofibroma derived Schwann Cells reveals a secreted form of the RARRES1 protein.
Int J Mol Sci. 2012;13(7):9380-9399. doi: 10.3390/ijms13079380. Epub 2012 Jul 24.
8
The molecular biology of vestibular schwannomas and its association with hearing loss: a review.
Genet Res Int. 2012;2012:856157. doi: 10.1155/2012/856157. Epub 2012 Feb 20.
9
Therapeutics for childhood neurofibromatosis type 1 and type 2.
Curr Treat Options Neurol. 2011 Dec;13(6):529-43. doi: 10.1007/s11940-011-0142-9.

本文引用的文献

2
Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options.
Am J Med Genet A. 2009 Oct;149A(10):2327-38. doi: 10.1002/ajmg.a.33045.
3
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Clin Cancer Res. 2009 Aug 15;15(16):5032-5039. doi: 10.1158/1078-0432.CCR-08-3011. Epub 2009 Aug 11.
4
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
N Engl J Med. 2009 Jul 23;361(4):358-67. doi: 10.1056/NEJMoa0902579. Epub 2009 Jul 8.
5
Neurofibromatosis type 2 (NF2): a clinical and molecular review.
Orphanet J Rare Dis. 2009 Jun 19;4:16. doi: 10.1186/1750-1172-4-16.
6
Neurofibromatosis type 1.
J Am Acad Dermatol. 2009 Jul;61(1):1-14; quiz 15-6. doi: 10.1016/j.jaad.2008.12.051.
8
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.
Curr Opin Genet Dev. 2009 Jun;19(3):230-6. doi: 10.1016/j.gde.2009.04.001. Epub 2009 May 19.
10
PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.
Exp Neurol. 2009 Jul;218(1):137-44. doi: 10.1016/j.expneurol.2009.04.019. Epub 2009 May 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验